How could Medicare's coverage approval for Leqembi affect Joe Biden's administration?
The Leqembi coverage approval demonstrates the administration's regulatory reach over Medicare. The approval of coverage for Leqembi by Medicare is an implementation of the regulatory policies set by the administration. CMS covers the drug for eligible patients with mild cognitive impairment or mild Alzheimer's dementia, provided they have confirmed amyloid plaque and their neurologist participates in an approved registry. While this expands access to a critical treatment from Biogen and Eisai, patients with Original Medicare who lack supplemental coverage may still face high costs, potentially reaching thousands of dollars due to 20% coinsurance on the roughly $28,270 list price.
- Effect
- Mixed
- How direct
- Brind's reasoning
- When
- Right away
- The story
- No new developments lately
How it reaches Joe Biden
-
Medicare approved coverage for Leqembi, a drug from Biogen and Eisai, under specific conditions. Coverage requires that the patient has confirmed amyloid plaque and that the neurologist reports to an approved registry. The drug has a list price of approximately $28,270 annually.
The full event1independent outlet -
Medicare is regulated by the administration, which mandates specific policies such as drug price negotiation and subsidy programs. This coverage approval is a direct operational result of the administration's regulatory authority over the federal health insurance program.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
46th President of the United States (2021–2025)
Everything about Joe Biden
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Medicare covers Leqembi only if the patient has confirmed amyloid plaque and the neurologist reports to an approved registry.aol.com
- Leqembi lists for about $28,270 a year for a patient weighing 165 pounds.aol.com
- Original Medicare has no out-of-pocket cap, meaning 20% coinsurance could reach thousands of dollars.aol.com
- Changes to Medicare coverage take effect January 1, 2027.aol.com
Why it matters
For the administration, this approval represents a tangible step toward increasing access to critical, high-cost treatments for Alzheimer's patients, aligning with policy goals regarding drug availability. However, the complexity of the coverage—requiring specific registries and potentially leaving Original Medicare patients with high out-of-pocket costs—also highlights the ongoing challenges in balancing drug access with financial sustainability within the Medicare framework.
This case is part of a broader regulatory landscape where federal programs like Medicare manage the reimbursement and access of advanced pharmaceuticals. The approval demonstrates the administrative power to dictate terms of coverage, but the financial burden on patients without supplemental insurance shows the structural hurdles that remain in the U.S. healthcare system.
What we don't know yet
- How will the required registry participation affect the speed of treatment access for patients?
- What specific policy changes might be needed to mitigate the high out-of-pocket costs for Original Medicare patients?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- aol.comNov 7
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.